<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="0" ids="18257">Ornithine</z:chebi> decarboxylase (<z:mp ids='MP_0010716'>ODC</z:mp>), a key enzyme in <z:chebi fb="0" ids="51349">polyamine</z:chebi> biosynthesis, is induced in ischemic tissue and may mediate vasogenic <z:hpo ids='HP_0000969'>edema</z:hpo> and delayed neuronal <z:hpo ids='HP_0011420'>death</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>We determined the effects of alpha-difluoromethylornithine (DFMO), a specific inhibitor of <z:mp ids='MP_0010716'>ODC</z:mp>, on <z:mpath ids='MPATH_124'>infarct</z:mpath> size and <z:mp ids='MP_0010716'>ODC</z:mp> activity in a rat model of transient focal <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>DFMO blocked the <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>-induced increase in <z:mp ids='MP_0010716'>ODC</z:mp> and significantly reduced <z:mpath ids='MPATH_124'>infarct</z:mpath> volumes by 57-45%, depending upon the treatment regimen </plain></SENT>
<SENT sid="3" pm="."><plain>These studies suggest that <z:chebi fb="0" ids="51349">polyamine</z:chebi> metabolism plays a role in the development of <z:e sem="disease" ids="C0007785" disease_type="Disease or Syndrome" abbrv="">cerebral infarction</z:e> after focal <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> and that DFMO may be useful in limiting injury after a <z:hpo ids='HP_0001297'>stroke</z:hpo> </plain></SENT>
</text></document>